An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

In the real-world setting, there is suboptimal compliance with treatments that require frequent administration and assessment visits. This undertreatment frequently has negative consequences in eye disease and carries a real risk to vision. For example, patients with glaucoma risk progression of vis...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2022-06, Vol.36 (6), p.1154-1167
Main Authors: Ghanchi, Faruque, Bourne, Rupert, Downes, Susan M, Gale, Richard, Rennie, Christina, Tapply, Ian, Sivaprasad, Sobha
Format: Article
Language:English
Subjects:
Age
Angiogenesis Inhibitors
Artificial Intelligence
Bevacizumab
Degeneration
Diabetes mellitus
Edema
Eye diseases
Gene therapy
Glaucoma
Glaucoma - chemically induced
Glaucoma - drug therapy
Humans
Intravitreal Injections
Kinases
Macular Edema - drug therapy
Occlusion
Patients
Platelet-derived growth factor
Ranibizumab - therapeutic use
Retina
Review
Rho-associated kinase
Steroid hormones
Uveitis
Uveitis - drug therapy
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A
Vision
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the real-world setting, there is suboptimal compliance with treatments that require frequent administration and assessment visits. This undertreatment frequently has negative consequences in eye disease and carries a real risk to vision. For example, patients with glaucoma risk progression of visual loss even with a small number of missed doses, and patients with neovascular age-related degeneration (nAMD) who fail to attend a bi-monthly clinic appointment to receive an intravitreal anti-vascular endothelial growth factor (VEGF) drug injections may lose the initial vision gains in vision. Protracted regular treatment schedules represent a high burden not only for patients and families, but also healthcare professionals, systems, and ultimately society too. There has been a clear need for longer-acting therapies that reduce the frequency, and therefore the burden, of treatment interventions. Several longer-acting interventions for nAMD, diabetic macular oedema, retinal vein occlusion, uveitis and glaucoma have either been developed or are in late-phase development, some of which employ novel mechanisms of actions, and all of which of promise longer (≥3 month) treatment intervals. This review delivers an overview of anti-VEGF agents with longer durations of action, DARPins, bispecific anti-VEGF/Ang2 therapies, anti-PDGF and anti-integrin therapy, Rho-kinase inhibitors, the Port Delivery System, steroids, gene therapy for retina and uveitis, and for glaucoma, ROCK inhibitors, implants and plugs, and SLT laser and MIGS. The review also refers to the potential of artificial intelligence to tailor treatment efficacy with a resulting reduction in treatment burden.
ISSN:0950-222X
1476-5454
DOI:10.1038/s41433-021-01766-w